A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Hui Xu et al.|British Journal of Dermatology|2024Cited by 21
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasisYu Chen, Gang Wang, Furen Zhang et al.|International Immunopharmacology|2022Cited by 12
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trialLunfei Liu, Min Zheng, Chunlei Zhang et al.|European Journal of Dermatology|2020Cited by 5